All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

ESH 2019 | How do you integrate molecular diagnostics in clinical practice?

Nov 1, 2019

The AML Global Portal were delighted to speak to Peter Valk, Erasmus University Medical Center, Rotterdam, NL, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Peter Valk: How do you integrate molecular diagnostics in clinical practice?

Peter Valk discusses the role of Next Generation Sequencing (NGS) in clinical decision- making in AML. He explains the important role of NGS in routine molecular-based diagnostics, prognostic and response monitoring such as measuring the presence or absence of whole genes and monitoring somatic and germline mutations.

How do you integrate molecular diagnostics in clinical practice?